| Certification: | GMP |
|---|---|
| Grade Standard: | Medicine Grade |
| Type: | API |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Lincomycin hydrochloride - A Unique Pharmaceutical Marvel Lincomycin hydrochloride unveils itself as an exquisite white crystalline powder, exuding a subtle yet distinct aroma accompanied by a slightly bitter taste. This remarkable substance is fully soluble in water and methanol, showcasing its versatility. Its hydrochloride salt form is frequently used in feed applications, demonstrating its adaptability. The production of this alkaline lincosamide antibiotic occurs during the growth phase of the Streptomyces genus, specifically Streptomyces lincolnensis, accentuating its natural origins and potency.
| Basic Information | |
| Product name | Lincomycin Hydrochloride |
| Grade | Pharmaceutical Grade |
| Appearance | White crystal powder |
| Assay | 99% |
| Shelf life | 3 Years |
| Packing | 25kg/drum |
| Condition | stored in a cool and dry place |
Lincomycin hydrochloride primarily combats infections induced by Gram-positive bacteria, excelling in cases involving penicillin-resistant strains. It proves effective in addressing poultry respiratory issues stemming from Mycoplasma, swine enzootic pneumonia, and anaerobic infections such as chicken necrotizing enterocolitis. This makes it an indispensable tool in the veterinary pharmaceutical arsenal.
Additionally, this potent antibiotic is employed in treating treponema dysentery, toxoplasmosis, and actinomycosis in dogs and cats, further showcasing its broad-spectrum efficacy and essential role in veterinary medicine.
Originating from the actinomycete Streptomyces lincolnensis, Lincomycin is a powerful lincosamide antibiotic. Its derivative, clindamycin, is created by substituting the 7-hydroxy group with an atom that inverts chirality, illustrating the sophisticated chemical adaptation that enhances its therapeutic capabilities.
Lincomycin stands out from macrolides with its similar structure, antibacterial spectrum, and action mechanism, yet it extends its effectiveness against additional organisms like actinomycetes, mycoplasma, and select Plasmodium species. A single 600 mg intramuscular dose achieves peak serum levels of 11.6 micrograms/ml within 60 minutes, sustaining therapeutic levels for 17 to 20 hours for most susceptible Gram-positive organisms. Urinary excretion post-dose varies from 1.8 to 24.8 percent, averaging 17.3 percent, emphasizing its efficient pharmacokinetic profile.
1. Oral formulations perfectly address respiratory, abdominal, female reproductive tract, pelvic, skin, and soft tissue infections caused by sensitive strains like Staphylococcus aureus and Streptococcus pneumoniae, making it an essential choice for targeted therapies.
2. For severe infections, the injectable formulation provides robust treatment against streptococcus, pneumococcus, and staphylococcus, becoming a critical component in surgical adjuvant therapies for septicemia, bone and joint infections, and Staphylococcus-induced acute hematogenous osteomyelitis.
3. Lincomycin hydrochloride also serves as an optimal alternative for patients allergic to penicillin or those who cannot receive penicillin-type medications, ensuring comprehensive care for all patients.
){kind=link}